BOWIE, Md., June 3, 2026 /PRNewswire/ -- The Epilepsy Foundation of America is proud to announce that Joyce A. Cramer...
Collaboration's initial focus will focus on two antibody programs targeting CNS diseases VALBY, Denmark and AMSTERDAM, June 3, 2026 /PRNewswire/ --...
SAN DIEGO, June 03, 2026 (GLOBE NEWSWIRE) -- Denovo Neuroscience, a pioneer in applying precision medicine in central nervous system...
SAN DIEGO, June 03, 2026 (GLOBE NEWSWIRE) -- Denovo Neuroscience, a pioneer in applying precision medicine in central nervous system...
New findings from the industry’s largest real-world TMS database reinforce NeuroStar’s leadership in advancing evidence-based mental health careMALVERN, Pa., June...
XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement...
– Comes just weeks after Firefly confirmed its active public-private partnership with the U.S. Department of War – KENMORE, N.Y,...
Presentation by leading expert Andrew J. Cutler, MD, will examine the lifelong impact of ADHD, risks of leaving the condition...
Further Strengthens Company’s Medical Depth and Therapeutic ExpertiseMORRISVILLE, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Syneos Health®, a leading fully...
ROSELAND, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American: MLSS), a leading developer of computerized drug...
Hartford HealthCare becomes one of the first clinically integrated networks in the region to include MinuteClinic as an in-network primary...
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, May 25, 2026...
TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF) (“PharmAla” or the “Company”), a...
Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic...
NEW YORK, NY / ACCESS Newswire / May 19, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company developing...
NEW YORK, NY / ACCESS Newswire / May 19, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company developing...
Veteran physician, medical affairs and clinical research leader brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience,...
TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that...
Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically significant sustained duration of effect...
Federal Officials, Researchers, Clinicians and Biopharma Leadership Convened by Psychedelic Medicine Coalition at the National Press Club Vancouver, Canada, May...